Treatment small-cell lung cancer chemotherapy regimen weekly intervals Southwest Oncology Group pilot study intensive weekly treatment regimen patients small-cell lung cancer SCLC active chemotherapeutic agents disease doxorubicin DOX cyclophosphamide CTX vincristine VCR cisplatin CDDP MTX goal program rapid repetitive exposure active drugs Treatment total weeks Seventy-six SCLC patients limited disease extensive disease overall complete partial response rate Complete response rates patients limited LD extensive disease ED median survivals patients LD ED months Toxicities tolerable Twenty-six patients transient life-threatening toxicities patient fatal toxicity Eighty-four percent patients protocol entire treatment period intensive short-duration treatment regimen good standard regimens complete response rate median survival patients ED SCLC 